Mersana Therapeutics — Technical Presentation (January 2025)
22 slides from Mersana Therapeutics's technical presentation, Jan 10, 2025
Slide 1: Initial Phase 1 Dose Escalation Data for Emi-Le (XMT-1660)
Initial Phase 1 Dose Escalation Data for Emi - Le ( emiltatug ledadotin ; XMT - 1660) January 10, 2025
Slide 2: Legal Disclaimer
Legal Disclaimer 2 This presentation contains “forward - looking” statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 . These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts
Slide 3: Mersana focused on novel ADC platforms and payloads
3 While today’s ADCs provide substantial benefits to some patients, significant platform and payload limitations remain. Mersana is focused on developing novel platforms and payloads that enable ADCs with meaningfully improved safety and efficacy. ADCs, antibody - drug conjugates
Slide 4: Innovating to Overcome Today's ADC Limitations
Lack of Platform and Payload Innovation Cytotoxic ADCs remain predominant with few novel mechanisms Innovating to Overcome Today's ADC Limitations 4 ADC, antibody - drug conjugate; ILD, interstitial lung disease; IO, immuno - oncology; STING, STimulator of INterferon Genes; topo - 1, topoisomerase -
Slide 5: Background on B7-H4 and Emi-Le
Background on B7 - H4 and Emi - Le B7 - H4 Target: Clinically validated and highly expressed in a range of solid tumors with limited healthy tissue expression • Novel ADC Design: Homogeneous DAR 6 Dolasynthen ADC (site - specific bioconjugation; proprietary auristatin payload) • Two FDA Fast Track D
Slide 6: Emi-Le Phase 1 key findings summary
• Most common TRAEs: transient AST increase; low - grade nausea and fatigue; generally asymptomatic and reversible proteinuria • No Grade 4 or Grade 5 TRAEs reported; no dose - limiting treatment - related neutropenia, neuropathy, ocular toxicity, ILD or thrombocytopenia reported • Profile may enabl
Slide 7: Trial Design and Demographics
Trial Design and Demographics
Slide 8: Emi-Le Phase 1 Dose Escalation Design
Emi - Le Phase 1 Dose Escalation Design 8 • In parallel with DES, backfill cohorts are enrolling additional participants at multiple dose levels • Each backfill cohort is enrolling up to 12 patients and may focus on tumor types of particular interest • Data from both DES and backfill cohorts will be
Slide 9: Phase 1 Dose Escalation and Backfill Enrollment
Broad range of doses and multiple dosing schedules investigated Phase 1 Dose Escalation and Backfill Enrollment 9 Doses and Schedules Investigated (in mg/m 2 per cycle) 67.4 (n=4) 80.0 (n=11) 95.0 (n=5) 38.1x2 (n=9) 44.5x2 (n=10) 1 38.1 (n=12) 44.5 (n=8) 50.7 (n=14) 59.0 (n=14) 67.4 (n=15) 28.7x2 (n
Slide 10: Dose Escalation and Backfill Demographics
Majority of patients had breast cancer and received ≥1 prior topo - 1 ADC Dose Escalation and Backfill Demographics 10 1. 11 of 63 (17%) of TNBC patients had a primary diagnosis of HR+ breast cancer 2. For this preliminary analysis, TPS ≥70 determined to be “TPS high”. Final B7 - H4 TPS cutoff for E
Slide 11: Safety and Tolerability
Safety and Tolerability
Slide 12: Safety Profile: Generally Well Tolerated With No Grade 4 or 5 TRAEs
Safety Profile: Emi - Le Observed to be Generally Well Tolerated With No Grade 4 or 5 TRAEs 12 Note: Two Grade 5 treatment - emergent events, both deemed unrelated by the investigators (1 unrelated case of non - neutropenic sep sis in a patient with underlying inflammatory bowel disease, 1 respirato
Slide 13: Differentiated Safety Profile: Treatment-Related Adverse Events
Differentiated Safety Profile: Treatment - Related Adverse Events Observed in ≥10% of Patients 13 December 13, 2024 data cutoff High Dose Range ≥76.2 mg/m 2 per cycle (N=38) Intermediate Dose Range 38.1 – 67.4 mg/m 2 per cycle (N=76) All Doses (N=130) Percentage (%) of Patients (N=130) (N=76) (N=38)
Slide 14: Clinical Activity Data
Clinical Activity Data
Slide 15: Best Change in Target Lesion Size waterfall
c c c c cc u c c u -100 -80 -60 -40 -20 0 20 40 60 80 100 120 B e s t C h a n g e i n T a r g e t L e s i o n S i z e f r o m B a s e l i n e ( % ) TPS Not Yet Determined (N=12) TPS >70 (N=40) TPS <70 (N=44) <38.1 mg/m2 38.1 - 67.4 mg/m2 >76.2 mg/m2 (N=14) (N=61) (N=21) Notes: a) Evaluable populatio
Slide 16: Emi-Le Shown to be Clinically Active in Heavily Pretreated Patients
Emi - Le Shown to be Clinically Active in Heavily Pretreated Patients 16 Dose Range Known B7 - H4 Expression Subtherapeutic <38.1 mg/m 2 per cycle High ≥76.2 mg/m 2 per cycle Responses/Evaluable Patients with Known B7 - H4 Status (ORR%) Intermediate 38.1 – 67.4 mg/m 2 per cycle B7 - H4 Low B7 - H4 H
Slide 17: Intermediate Dose Range: Clinical Activity in B7-H4 High Tumors
0 4 8 12 16 20 24 28 Weeks -100 -80 -60 -40 -20 0 20 40 60 80 100 120 % C h a n g e i n S u m o f T a r g e t L e s i o n D i a m e t e r s ACC-I (N=3) Ovarian (N=3) Endo (N=4) HR+BC (N=3) TNBC (N=13) Intermediate Dose Range: Encouraging Clinical Activity in Evaluable Patients With B7 - H4 High Tumo
Slide 18: Intermediate Dose Range: Clinical Activity in B7-H4 High TNBC
T T T T T T T TT TT TT T T 3 5 4 5 4 5 4 4 5 4 5 4 PR PR PR -100 -80 -60 -40 -20 0 20 40 60 80 100 120 B e s t C h a n g e i n T a r g e t L e s i o n S i z e f r o m B a s e l i n e ( % ) Intermediate Dose Range: Encouraging Clinical Activity in Evaluable Patients With B7 - H4 High TNBC 18 December
Slide 19: Expansion Enrollment Now Underway in Post-Topo-1 TNBC
Expansion Enrollment Now Underway at 67 mg/m 2 Q4W in Post - Topo - 1 TNBC 19 Primary Objectives: Assess safety, tolerability and preliminary antitumor activity Secondary Objectives: Assess PK and ADA • Advanced or metastatic TNBC • 1 to 4 prior lines of treatment, including at least one prior topo
Slide 20: High Dose Range: Preliminary Data Suggest Potential for Greater Clinical Activity
High Dose Range: Preliminary Data S uggest P otential for Even Greater Clinical Activity 20 December 13, 2024 data cutoff The two patients above with unconfirmed partial responses ( uPRs ) progressed upon their confirmatory scans following the data cutoff. 1. Bardia et al. NEJM 2021 April 22; 384(16
Slide 21: Expected 2025 Milestones and Areas of Focus
• 1H2025: Continue expansion enrollment at 67.4 mg/m 2 Q4W in TNBC patients who have previously received at least one topo - 1 ADC • 2025: Initiate expansion enrollment at second dose in post - topo - 1 TNBC • 2025: Present additional Phase 1 dose escalation and backfill cohort clinical data • Conti
Slide 22: Q&A Session
Q&A Session Thank you to the patients, families, caregivers and investigators who are participating in this clinical trial 22
Mersana Therapeutics — Technical Presentation (January 2025) on 6ix